ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brimonidine

Also written as “Brimonidine”, “Brimonidine Tartrate” and “CD07805/47 Gel”.

Its studies are mostly in Glaucoma · Rosacea · Glaucoma, Open-Angle · Conjunctivitis, Allergic · Hyperemia, led by 10 companies.

Drug pageBrimonidine: every studyMany companies study it; this page follows only the 52 they lead. All 104 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 6, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only220 open or runningphase 4since Apr 6, 2007Sep 12, 2005none ahead
Galderma Group100 open or runningphase 4since Sep 23, 2014Jun 12, 2008none ahead
Bausch Health Companiesits history only70 open or runningphase 3since Oct 8, 2013Oct 8, 2013none ahead
Eye Therapiesits history only30 open or runningphase 2since Jan 10, 2011Jan 10, 2011none ahead
Ocugenits history only30 open or runningphase 3since Jul 9, 2018Oct 10, 2017none ahead
Alconits history only20 open or runningphase 4since Dec 1, 2008May 28, 2003none ahead
Tarian Pharmaits history only22 open or runningphase 2since Jan 23, 2025Jan 23, 2025none ahead
Biogenits history only10 open or runningphase 4since Oct 1, 2015Oct 1, 2015none ahead
Innovative Medicalits history only10 open or runningphase 4since Jun 30, 2006Jun 30, 2006none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Oct 31, 2014Oct 31, 2014none ahead

Also a collaborator on its studies: ORA and Eurotrials Brasil Consultores Cientificos Ltda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Galderma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2008First study: phase 2 study in Erythematous RosaceaFirst studyNCT00697541 · 20 enrolled · United States
  2. Sep 30, 2009Phase 2 study in RosaceaNCT00989014 · 122 enrolled · United States
  3. Jul 30, 2010Phase 2 study in RosaceaNCT01174030 · 269 enrolled · United States
  4. Mar 9, 2011Phase 3 study in RosaceaNCT01318733 · 449 enrolled · United States
  5. May 16, 20112 phase 3 studies in RosaceaNCT01355471, NCT01355458
  6. Jun 14, 2013Phase 3 study in ErythemaNCT01882712
  7. Sep 23, 2014Phase 4 study in RosaceaNCT02249065 · 205 enrolled · United States
  8. Nov 24, 2015Phase 4 study in RosaceaNCT02616250 · 190 enrolled · United States, Canada
  9. Jul 19, 2016Phase 4 study in Chronic Persistent Vascular Facial ErythemaNCT02856919 · 101 enrolled · Brazil

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 10 Galderma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02856919Chronic Persistent Vascular Facial Erythema · Brazil4CompletedFeb 8, 2017101
NCT02616250Rosacea · United States, Canada4CompletedSep 2016190
NCT02249065Rosacea · United States4CompletedAug 2015205
NCT01882712Erythema3WithdrawnSep 20150
NCT01355471Rosacea · United States, Canada3CompletedNov 2011293
NCT01355458Rosacea · United States, Canada3CompletedSep 2011260
NCT01318733Rosacea · United States3CompletedJun 2012449
NCT01174030Rosacea · United States2CompletedDec 2010269
NCT00989014Rosacea · United States2CompletedNov 2009122
NCT00697541Erythematous Rosacea · United States2CompletedJun 200820

How it is read

Names in the registry

  • “Brimonidine”, 4 entries
  • “Brimonidine Tartrate”, 4 entries
  • “CD07805/47 Gel”, 4 entries
  • “CD07805/47”, 3 entries
  • “400 µg Brimonidine Tartrate Implant”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.